Intercept Pharmaceuticals, Inc. (ICPT)’s Stock Is Buy After Today’s Big Increase

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Logo

Investors sentiment increased to 1.86 in 2019 Q1. Its up 0.46, from 1.4 in 2018Q4. It increased, as 24 investors sold Intercept Pharmaceuticals, Inc. shares while 35 reduced holdings. 40 funds opened positions while 70 raised stakes. 37.59 million shares or 96.09% more from 19.17 million shares in 2018Q4 were reported.
Artal Grp reported 50,000 shares stake. Birchview L P has 8,300 shares. American Int Gru Inc has 13,968 shares. Frontier Cap Ltd Liability Company reported 59,511 shares stake. 103,400 were reported by Pictet Asset Limited. Jpmorgan Chase And holds 748,985 shares or 0.02% of its portfolio. Ameriprise Financial Inc has 34,671 shares for 0% of their portfolio. Bb Biotech Ag holds 696,976 shares. Capital World Investors owns 0.01% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 213,137 shares. Guggenheim Limited Liability Corporation invested 0.03% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Neuberger Berman Gp Limited accumulated 3,500 shares. Sarissa Mngmt L P has invested 5.39% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Geode Cap Ltd Com holds 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) or 277,658 shares. Voloridge Invest Mngmt Lc reported 5,574 shares. Goldman Sachs Group Inc Incorporated has invested 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is a huge mover today! The stock decreased 0.82% or $0.54 during the last trading session, reaching $65.49. About 163,179 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 29.32% since August 14, 2018 and is downtrending. It has underperformed by 29.32% the S&P500.
The move comes after 8 months positive chart setup for the $2.14B company. It was reported on Aug, 14 by We have $70.07 PT which if reached, will make NASDAQ:ICPT worth $149.87 million more.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Among 14 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 9 have Buy rating, 1 Sell and 4 Hold. Therefore 64% are positive. Intercept Pharmaceuticals had 30 analyst reports since February 19, 2019 according to SRatingsIntel. The rating was maintained by Robert W. Baird with “Buy” on Tuesday, February 19. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Hold” rating given on Thursday, February 28 by RBC Capital Markets. The firm earned “Buy” rating on Friday, March 1 by Oppenheimer. The firm earned “Buy” rating on Tuesday, February 19 by Needham. The stock has “Buy” rating by Cantor Fitzgerald on Monday, March 11. The stock has “Buy” rating by Credit Suisse on Tuesday, February 19. Cantor Fitzgerald maintained the shares of ICPT in report on Thursday, February 28 with “Overweight” rating. Wells Fargo maintained the shares of ICPT in report on Tuesday, February 19 with “Hold” rating. Cantor Fitzgerald maintained it with “Buy” rating and $170 target in Tuesday, February 19 report. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Buy” rating given on Tuesday, February 19 by Oppenheimer.

More notable recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: which released: “3 Top Healthcare Stocks to Buy in July – Nasdaq” on July 24, 2019, also with their article: “The Daily Biotech Pulse: Sanofi’s Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering – Benzinga” published on August 06, 2019, published: “Noteworthy Thursday Option Activity: GM, GILD, ICPT – Nasdaq” on April 18, 2019. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were released by: and their article: “The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout – Benzinga” published on August 07, 2019 as well as‘s news article titled: “Intercept Pharma Q2 2019 Earnings Preview – Seeking Alpha” with publication date: August 06, 2019.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $2.14 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.